Proceedings and Voting Results of the 5th Annual General Meeting (AGM) ofPiramal Pharma Limited (the Company)

Piramal Pharma Limited held its 5th AGM on 30th July 2025 via video conferencing, chaired by Ms. Nandini Piramal. All 9 resolutions were passed with the required majority. Key items included adoption of FY25 audited financial statements, declaration of a final dividend of ₹0.14 per equity share (face value ₹10), and re-appointment of Ms. Nandini Piramal as director (96.21% in favour). Shareholders also approved the appointment of Suresh Surana & Associates LLP as statutory auditors (99.93% in favour) and Mr. Amit Jain as a Non-Executive, Non-Independent Director (96.54% in favour). The meeting also approved the re-appointment of Mr. Jairaj Purandare as Independent Director and the issue of Non-Convertible Debentures on a private placement basis, both passed as special resolutions with 98.45% and 99.45% votes in favour respectively. Out of 483,888 shareholders on record date, 11 from promoter group and 87 from public attended via VC. The meeting concluded at 4:15 p.m. after 15 minutes of e-voting.